Stock-based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of option granted during the period	1,318,948
Stock options description	The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market value.
Fair market value of common stock percentage	100.00%
Exercise prices ranging, lower limit	$ 2.30
Exercise prices ranging, upper limit	$ 3.15
Performance-based options outstanding	1,066,800
Unrecognized compensation expense	$ 2,700	$ 1,600
Unrecognized compensation expense recognized over a weighted-average period	3 years 3 months 19 days	2 years 6 months
Fair value option exercise price per share	$ 1.46	$ 3.24
Stock Appreciation Rights (SARs) [Member]
Number of option granted during the period	1,000,000
Stock option weighted-average period	10 years
Restricted Stock Units (RSUs) [Member]
Number of option granted during the period	500,000
2010 Stock Option Plan [Member]
Common stock, shares authorized	5,200,000
2018 Incentive Plan Activity [Member]
Number of common stock reserved for future issuance	5,000,000
Number of option granted during the period	411,000
Performance-based options outstanding	361,000
Fair value option exercise price per share	$ 2.21
2018 Incentive Plan [Member]
Stock options description	The exercise price of stock options granted under the 2018 Incentive Plan must be equal to the fair market of OncoCyte common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of OncoCyte stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years.
Fair market value of common stock percentage	110.00%
2018 Incentive Plan [Member] | Maximum [Member]
Stock options exercisable	$ 100